Clinical and laboratory characteristics of our mantle cell lymphoma patients: a cross sectional study

Creative Commons License

Oğuz Davutoğlu N., Gündüz E., Andıç N., Üsküdar Teke H.

Osmangazi Journal of Medicine, vol.43, no.1, pp.55-61, 2021 (Peer-Reviewed Journal)

  • Publication Type: Article / Article
  • Volume: 43 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.20515/otd.759341
  • Journal Name: Osmangazi Journal of Medicine
  • Journal Indexes: TR DİZİN (ULAKBİM)
  • Page Numbers: pp.55-61
  • Eskisehir Osmangazi University Affiliated: Yes


Mantlecelllymphoma (MCL) compriseslessthan 10% of non-Hodgkin’slymphomacases. Majorindependent risk factorsareidentified as the MCL International Prognostic Index (MIPI) and Ki-67 proliferationindex of tumor. Theaim of thisstudy is retrospectivelyevaluate MCL patientstreatedandfollowed-up in ourdepartment. MaterialsandMethods: Thisstudyincluded 27 MCL patientsmedicalrecords of whomcould be reached. Thedatawasreviewedtofigureout MIPI score, bone marrowinvolvement, extranodalinvolvement, treatmentprotocols, treatmentresponse, relapsestatus, andtransplanthistory. Patientswerefollowed-upfor a meanduration of 64.4 (1-246) months. Subsequenttothefirst-linetreatment, completeresponsewasachieved in 17 (63%) andpartialresponsewasachieved in 3 (11%) patients, whereas 7 (26%) patientsexperienceddiseaseprogression. Median PFS followingfirst-linetreatmentwas 29 (3-120) months. Based on theclassificationby MIPI scoring, low-risk patients had significantlylongermediansurvivalthanthat of high-risk patients (194 monthsvs 126 months, p=0.04), andthepatients at moderate-risk had significantlylonger PFS comparedtohigh-risk patients (41month vs 3 months, p=0.025). Medianage, stage III-IV, andshortduration of PFS in patientswithhigh MIPI scorewereourfindings in parallelwithavailableliterature. R-hyper-CVAD/MTX-AraCwasmostlypreferredfirst-linetreatment at ourcenterwith a shortermedian PFS comparedtoliterature. Giventheexpandinguse of target-driventherapiesfor MCL, webelieveourresultsarenoteworthy in comparingsuchtherapieswithpre-existingtherapies.